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http://www.cmjournal.org/content/9/1/20RESEARCH Open AccessPanax ginseng therapy for chronic obstructive
pulmonary disease: a clinical trial protocol and
pilot study
Lei Wu1, Anthony Lin Zhang2, Yuan Ming Di2, Johannah Linda Shergis2, Yuanbin Chen1, Xinfeng Guo1,
Zehuai Wen1, Francis Thien3, Christopher Worsnop4, Lin Lin1* and Charlie Changli Xue2*Abstract
Background: Panax ginseng (Ren shen) has been used to treat chronic obstructive pulmonary disease (COPD). This
article aims to present a study protocol and pilot trial comparing P. ginseng with placebo for treating moderate to
very severe COPD.
Methods: COPD was diagnosed spirometrically, with participants having a forced expiratory volume in one second
(FEV1) of between 20% and 79% and FEV1 to forced vital capacity (FVC) ratio of less than 70%. Outcome measures
included exacerbation rate, St. Georges Respiratory Questionnaire, COPD Assessment Test and Short-form Health
Survey (SF-36). Other outcome measures included the six-minute walk test, FEV1, FVC, relief medication use, use of
COPD-specific medical resources, and adverse events. The study is a randomized, double-blind, placebo controlled
clinical trial. The method of this pilot trial was based on a planned full-scale trial except that participants were
enrolled for ten weeks compared to 52 weeks. In the pilot trial, 14 participants (57–73 years old) with moderate to very
severe COPD were recruited from a community health program at a public Chinese medicine hospital in Guangdong
Province, China. After a 2-week run-in period, 10 participants were eligible for the study and were randomly assigned
to either P. ginseng group (n = 5) (200 mg twice daily for four weeks) or placebo group (n = 5), and then followed-up
for an additional 4 weeks for a total of 10 weeks.
Results: Nine participants completed the trial and one dropped out. The exacerbation rate could not be evaluated
because there were no exacerbations. One participant in P. ginseng group reported events of sore throat, cough and
fever. Trial investigators did not consider these events as COPD exacerbations or adverse events.
Conclusions: Participant recruitment, study design, data collection and outcome measurement have been tested in a
pilot trial. A full-scale trial is warranted.Background
Chronic obstructive pulmonary disease (COPD) is char-
acterized by breathlessness, coughing, and excess sputum
production [1]. There are 64 million people suffering from
COPD worldwide and COPD is predicted to be the third
leading cause of death by 2030 [2].* Correspondence: drlinlin620@163.com; charlie.xue@rmit.edu.au
1Guangdong Provincial Hospital of Chinese Medicine, Guangdong 510120,
China
2Traditional and Complementary Medicine Program, School of Health
Sciences and Health Innovations Research Institute (HIRi), RMIT University, PO
Box 71, Bundoora, Victoria 3083, Australia
Full list of author information is available at the end of the article
© 2014 Wu et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.COPD patients often use inhaled bronchodilators to
relieve symptoms, and inhaled glucocorticoids to treat
and prevent frequent exacerbations [1]. New treatments
targeting the underlying chronic inflammatory pathways
are being developed [3]. A phosphodiesterase-4 (PDE-4)
inhibitor, roflumilast (trade names Daxas/Dalisresp), is
used to treat COPD, although it has adverse effects, such
as nausea, reduced appetite and abdominal pain [1].
Several systematic reviews indicated P. ginseng im-
proved lung function (forced expiratory volume in one
second, FEV1) and quality of life measured by the St.
George's Respiratory Questionnaire (SGRQ), compared
to pharmacotherapy alone [4,5]. Studies investigating
P. ginseng for COPD and other related diseases such as. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and colleagues demonstrated that P. ginseng (G115,
100 mg) twice daily for 12 weeks improved pulmonary
function tests, and respiratory endurance in 92 mod-
erate COPD participants [6]. Scaglione and colleagues
evaluated P. ginseng in two studies. The first in-
volved 40 chronic bronchitis participants and found
that P. ginseng (100 mg) twice daily for 8 weeks had fewer
alveolar macrophages in bronchoalveolar lavage fluid
than those who took placebo [7]. The second study in-
volved 75 participants with acute exacerbation of chronic
bronchitis and found that those who took P. ginseng
(G115, 100 mg) twice daily with antibiotics for 9 days
had a lower bacterial count than those who took antibi-
otics alone [8]. In addition, no severe side effect was re-
ported in the P. ginseng treatment [9]. Despite positive
results, these studies did not evaluate appropriate COPD
outcomes, such as health-related quality of life and rates
of exacerbation.
We previously designed randomized clinical trials (RCT)
to evaluate P. ginseng’s effectiveness in treating moderate
COPD [10] and identified methods to integrate Chinese
medicine in hospital-based clinical trials [11]. This study
aims to present the protocol and a pilot trial comparing




We included participants who were aged between 40
and 80 years; had a post-bronchodilator FEV1 of ≤ 20%
and < 80% of predicted normal values and had a FEV1 to
forced vital capacity (FVC) ratio (FER) of less than 70%;
were clinically stable and had not experienced an acute
exacerbation of COPD for at least 4 weeks before the
trial and had not been hospitalised in the past six
months with three or more exacerbations; and met the
Chinese medicine diagnostic criteria for lung qi defi-
ciency with or without spleen or kidney qi deficiency.
We excluded participants who had a history of asthma
or chronic systemic infections or inflammatory condi-
tions other than COPD that require systemic corticoster-
oid treatment in the last 3 months; were pregnant,
breast-feeding or intending to become pregnant during
the course of the study; had a serious illness such as se-
vere heart, liver or kidney disease; were taking long-term
immunosuppressive agents or immune-stimulants; had
an allergic history to ginseng or currently were taking
ginseng; were users of monoamine oxidase inhibitor an-
tidepressants, anticoagulants and/or antihyperglycaemic
medications; and had undertaken pulmonary rehabilita-
tion within three months of the commencement of the
study or intended to enter pulmonary rehabilitation dur-
ing the study.Design
This pilot trial was designed to test the practicality of a
full-scale trial that was planned to be conducted in a
public hospital in China. The only difference between
the pilot trial and the full-scale trial is the trial duration,
being 10 weeks for the pilot and one year for the full
scale trial.
The participants with moderate, severe or very severe
COPD (Global Initiative for Chronic Obstructive Lung
Disease [GOLD], stage II-IV) [1] were recruited from
the Guangdong Provincial Hospital of Chinese Medicine,
Guangdong Province, China. The participants who pro-
vided informed consent were enrolled for 10 weeks:
2 weeks for run-in; 4 weeks for treatment; and 4 weeks
for follow-up. The participants meeting all the criteria
entered a 2-week run in period. They were randomized
to P. ginseng or placebo if they were stable and had no
COPD exacerbation during the 2-week run in period.
Visits were scheduled for baseline, end of run-in (week 2),
end of treatment (week 6) and end of follow-up (week 10)
(Figure 1). In the full-scale trial participants will be enrolled
for 52 weeks, four weeks run-in, 24 weeks treatment and
24 weeks follow-up (Figure 2). They will attend 6 visits:
baseline, randomisation, mid-treatment, end of treatment,
mid follow-up and end of follow-up.
Ethical approval (B2012-49-01) was obtained from the
Guangdong Provincial Hospital of Chinese Medicine
Human Research Ethics Committee (Additional files 1
and 2). The pilot trial has been registered with the
Australian and New Zealand Clinical Trials Registry
(ACTRN: 12614000029695).
Random assignment and blinding
A list of randomisation numbers was generated by a
statistician using statistical software (SPSS, Windows
Version 20.0; IBM Corp., Armonk, NY). This process
tested the effectiveness of keeping participants, investi-
gators, medical staff, and other staff blinded to the study
allocation. Opaque envelopes containing a number con-
cealed to the treatment allocation was used to randomly
assign participants to either P. ginseng or placebo group.
Medications were put in packages that concealed the
randomization code and were dispensed from the hospi-
tal’s central pharmacy by pharmacists who were blinded
to allocation.
Interventions
Participants in the intervention group received standar-
dised P. ginseng extract, G115, in capsule form 200 mg
twice daily and participants in the control group re-
ceived placebo for 4 weeks. P. ginseng G115 is manufac-
tured according to Good Manufacturing Practices by
Ginsana SA, Switzerland. The lactose-based placebo
was also manufactured by Ginsana SA and matched in
Figure 1 Flow chart describing study design and participant selection in the pilot trial.
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tions would be dispensed for 24 weeks.
P. ginseng, G115, is the highest quality standardised
extract and has been evaluated in more than 46 clinical
studies over 35 years [12]. G115 is standardised to con-
tain 4% ginsenosides, Rg1, Rb1, Re, Rf, Rg2, Rc, Rb2, and
Rd. The dosage in this study was determined by referen-
cing the clinical trial literature and recommendations
from the manufacturer [13].
Throughout the study, participants were given the
short-acting β2-agonist Ventolin (salbutamol) to relieve
symptoms as needed. Respiratory drugs, including long-
acting anticholinergics or long-acting β2-agonists alone
or in combination with glucocorticoids, could be usedthroughout the study under the advice of the partici-
pants’ respiratory physicians. Other respiratory drugs,
such as short-acting anticholinergics, short-acting β2-
agonists other than salbutamol, theophylline, cortico-
steroids as monotherapy, antibiotics, mucolytics and
antitussives were not allowed during the study. The fol-
lowing medications for other conditions were also not
allowed during the study: immunotherapy, monoamine
oxidase inhibitor antidepressants, anticoagulants, antihy-
perglycaemics, and other Chinese herbal medicines.
Outcome measures
The primary outcome measure was rate of exacerbation,
which was defined as a change in baseline dyspnoea,
Figure 2 Flow chart for a full-scale trial.
Wu et al. Chinese Medicine 2014, 9:20 Page 4 of 8
http://www.cmjournal.org/content/9/1/20cough and/or sputum [14]. Specifically, exacerbations in-
volving two or more symptoms, such as worsening dys-
pnoea and an increase in sputum purulence or volume
or both, or any single major symptom and more than
one minor symptom such as upper airway infection, un-
expected fever or increased wheezing that lasted two or
more days [14]. Investigators (who are qualified respira-
tory research assistants) phoned the participants at the
end of every week and reviewed their participant diary at
each visit to determine if a participant had experienced
an exacerbation. Investigators prescribed medications to
treat exacerbations if needed. Exacerbation severity was
categorised as mild (easily tolerated by participant, caus-
ing minimal discomfort), moderate (discomfort signifi-
cant enough to interfere with daily activities) or severe
(incapacitating, unable to work or perform daily activities).
Exacerbations were not considered adverse events unless
they were serious (e.g., fatal, life threatening, perman-
ently incapacitating or left participants needing prolonged
hospitalisation).
Secondary outcomes were health status measured
with the St. Georges Respiratory Questionnaire (SGRQ),
COPD Assessment Test (CAT), the Short-form Health
survey (SF-36) and exercise tolerance using the 6-minute
walking test (6MWT). Other outcomes included change
in postbronchodilator FEV1 and FVC, use of relief medi-
cation, and COPD-specific medical resource use, in-
cluding emergency department presentations and medicalpractitioner visits. Safety assessments included investigator
inquiries about the occurrence of adverse events and blood
samples, which included a full blood count and liver/
kidney function tests taken before and after treatment.
All outcome measures were collected by the same in-
vestigator for continuity and to aid in maintaining a
standard procedure. Outcome measures were selected
based on the anticipated full-scale trial. For a full-scale
trial the sample size and adequate statistical power would
be based on a study evaluating carbocisteine for acute ex-
acerbations of COPD [15].
Statistical analysis
Outcome measures were analysed by t test at the end of
each time point. SPSS, Windows Version 20.0 (IBM
Corp., Armonk, NY) was used to analyse the data for
the outcome measures. Last Observation Carried Forward
(LOCF) was used to evaluate data with an intention-to-
treat analysis. Data were presented as mean and standard
deviation. The aim of this pilot trial was to test the practi-
cality of trial design, it would be inappropriate to make any
inferences or state findings of any efficacy. Data were only
analysed to make the investigators aware of any issues that
needed to be overcome in the planned larger-scale trial.
Results of the pilot trial
We recruited 14 participants from a community health
program at the Guangdong Provincial Hospital of Chinese
Medicine in May and June of 2012. After the 2-week
run in period, 10 of these participants were eligible for
the study and were randomly assigned to P. ginseng
group (n = 5) (200 mg twice daily for four weeks) or
placebo group (n = 5) (Figure 1). The four excluded
participants did not meet the inclusion criteria due to
their lung function and an exacerbation of COPD
symptoms during the run-in period and abnormal liver
function and a history of liver disease. The participants’
mean age was 64.8 years (range 57 to 73 years old). Nine
participants were male and one was female. One partici-
pant in the P. ginseng group dropped out at week three
because of work commitments. Nine participants were
classified as having severe COPD, one was classified as
having moderate COPD and none were classified as
having very severe COPD.
A qualified Chinese medicine respiratory specialist di-
agnosed the participants’ health according to Chinese
medicine. Seven participants were considered to have
lung and kidney qi deficiency, and three participants were
considered to have lung, spleen and kidney qi deficiency. At
the start of the study, two participants were taking antibi-
otics, eight were taking long-acting β-agonists, and nine
were taking inhaled corticosteroids. Because of the small
sample size, several baseline factors, including smoking
status and coughing severity, were imbalanced (Table 1).
Table 1 Baseline characteristics of the participants
Baseline assessment Treatment group (n = 5) Placebo group (n = 5)
Age (years) 67 ± 4 62.6 ± 4.15
Male/Female 5/0 4/1
Smoking status
Current smoker 3 0
Former smoker 1 5
Never smoked 1 0
FEV1 (L) (post bronchodilator) 1.38 ± 0.63 0.83 ± 0.10
FVC (L) (post bronchodilator) 2.79 ± 0.59 2.33 ± 0.36




Symptom severity Mild Mod Sev Mild Mod Sev
Shortness of breath 3 2 0 3 2 0
Cough 2 3 0 5 0 0
Sputum production 3 1 1 5 0 0
Antibiotics 0 2
Long-acting beta-agonists 3 5
Inhaled corticosteroids 3 5
Chinese medicine diagnosis
Lung and kidney qi deficiency 4 3
Lung, spleen and kidney qi deficiency 1 2
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during the short study duration (10 weeks). Health status
questionnaires (SGRQ, SF-36, and CAT) were unchanged
in both groups (see Table 2). All participants, except the
one who dropped out, completed the questionnaires andTable 2 Outcome measures
P. ginseng
(mean ± standard deviation)
Baseline End of treatment
Exacerbations Not applicable 0
FEV1 (L) 1.38 ± 0.63 1.40 ± 0.60
FVC (L) 2.79 ± 0.59 3.00 ± 0.50
FEV1/FVC 0.48 ± 0.13 0.40 ± 0.10
SGRQ 37.20 ± 12.85 32.20 ± 12.20
CAT (total score) 17.0 ± 6.32 16.20 ± 5.40
SF-36–General health 40.0 ± 23.18 48.00 ± 20.70
SF-36–Mental health 79.20 ± 17.75 82.40 ± 12.10
6MWT (m) 518.20 ± 10.01 502.80 ± 29.0
^End of treatment between groups comparison.
*P < 0.05 indicated significant difference between groups.
6MWT: 6-minute walking test, CAT: COPD Assessment Test, FEV1: forced expiratory
Questionnaire, SF-36: Short-form health survey (version 2).the result was evaluated by LOCF. The baseline question-
naire scores, except those for the SF-36 questions 2 and
3b, 3c, and 3e, were balanced between groups. There was
no significant difference in responses to the questionnaires
between groups at the end of treatment (see Table 2).Placebo
(mean ± standard deviation) P value^
Baseline End of treatment
Not applicable 0 1
0.83 ± 0.10 0.80 ± 0.06 0.06
2.33 ± 0.36 2.40 ± 0.46 0.11
0.36 ± 0.06 0.30 ± 0.06 0.14
45.80 ± 10.54 34.40 ± 8.20 0.74
17.20 ± 4.87 14.40 ± 2.70 0.67
37.0 ± 14.40 39.0 ± 18.50 0.49
86.40 ± 7.26 89.60 ± 6.60 0.49
453.20 ± 60.27 453.0 ± 20.50 0.01*
volume in 1 second, FVC: forced vital capacity; SGRQ: St Georges Respiratory
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treatment was not clinically important and the abso-
lute distance walked did not change. In the P. ginseng
group the mean distance walked at baseline was 518.2
meters and at the end of treatment it was 502.8 meters.
In the placebo group, the mean distance walked at
baseline and at the end of treatment did not change,
453 meters. There was also no change in mean FEV1,
FVC, or FEV1/FVC in the P. ginseng or placebo groups
(Figure 3). All participants used relief medication
(salbutamol) at some stage throughout the study. On
average, participants in the P. ginseng group used
4.82 ± 1.6 puffs per week and participants in the placebo
group used 2.06 ± 1.7 puffs per week. None of the partici-
pants needed to use any other COPD-related medical
resources.
There were no adverse events recorded from the study
medication. One participant in the P. ginseng group ex-
perienced a “common cold”, with symptoms of a sore
throat, cough and low-grade fever. This was not consid-
ered an exacerbation or related to the treatment. For the
nine participants, blood haematology and biochemistry
were unchanged after the treatment phase. The other
participant showed a slight increase in white blood cell
count and neutrophils. The result was not considered to
be clinically important.
Potential participants were relatively easy to identify.
The participants could not tell the difference between
the P. ginseng treatment and placebo. Those givenFigure 3 Lung function and SGRQ results: (A) mean post-bronchodila
(C) post-bronchodilator FEV1/FVC percentage and (D) SGRQ total sco
difference between groups at any time point.P. ginseng tolerated it well. Participants did not report
any issues in taking the dose twice a day for both groups
and did not report that the capsules tasted badly or were
hard to swallow. Despite multiple outcome measures, each
visit at the hospital by the participants lasted for no more
than 1.5–2 hours.
Discussion
This report presented a study protocol and the results of
a pilot trial comparing P. ginseng with placebo for mod-
erate to very severe COPD participants. The pilot trial
was run without major issue according to the study
protocol in a hospital environment in China.
The randomization process was successful and the use
of opaque envelopes to conceal allocation was effective.
The study procedures, including lung function, question-
naires, walking distance and blood tests were completed
at all of the time points. Response rates for data collec-
tion were high; the only missing response was that of
the participant who dropped out. No participants were
excluded on a Chinese medicine diagnosis in the inclu-
sion criteria.
Because of the small sample size and short study dur-
ation it was not surprising to observe no difference in
outcomes. A larger trial with proper treatment duration
according to the treatment principle would reveal the ac-
tual effect of P. ginseng in treating COPD. The planned
full-scale trial protocol will be conducted over one year
(6 months treatment and 6 months follow-up), similar to ator FEV1 in litres, (B) mean post-bronchodilator FVC in liters,
re. Error bars were standard deviations. There was no significant
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COPD [10].
A key consideration for any full-scale trials is recruit-
ment. In this pilot study, four out of 14 participants
(28%) did not meet the inclusion criteria. Recruitment
for a full-scale trial would succeed at a large hospital or
multiple sites. One participant withdrew from this study.
Participant withdrawals from long-term studies espe-
cially studies on COPD, are between 30% and 50% [16].
The outcome assessment in the pilot trial by only one
investigator performing all tests, including spirometry
using one device at the same time of day (8 a.m.–
12 p.m.) might be logistically unrealistic in the full-scale
trial. Therefore, standard operating procedures for all out-
comes would be necessary. The definition of exacerbation
severity should also be improved in a full-scale trial.
Based on the success of this pilot trial a full-scale trial
has been implemented at the Guangdong Provincial
Hospital of Chinese Medicine. The full-scale trial has
received ethical approval and has been registered with
the ANZCTR (ACTRN: 12613000382774). The sample
size for that full-scale trial was calculated according to
the effect size on rate of exacerbation in COPD patients
using a mucolytic agent (carbocisteine) in a randomized
controlled trial in China [15]. To potentially see a 30%
difference between the treatment and placebo with an
80% power and a two-tailed significance level of 5%. It
is estimated that a sample size of 100 participants per
group would be adequate.
Conclusions
Participant recruitment, study design, data collection
and outcome measurement have been tested in a pilot
trial. A full-scale trial is warranted.
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